Syk | Jotup

Kronos Bio and Gilead Sciences Enter Into Asset Purchase Agreement for Gilead's SYK Inhibitor Portfolio

Retrieved on:

Thursday, July 16, 2020

Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Enzymes, Tyrosine kinases, Syk, Acute myeloid leukemia, Gilead Sciences, Oncology, Tyrosine kinase inhibitors, Tyrosine kinase, Entospletinib

Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription, today announced that it has entered into an asset purchase agreement with Gilead Sciences, Inc. to acquire Gileads spleen tyrosine kinase (SYK) inhibitor portfolio.

Key Points:

Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription, today announced that it has entered into an asset purchase agreement with Gilead Sciences, Inc. to acquire Gileads spleen tyrosine kinase (SYK) inhibitor portfolio.
Kronos is uniquely positioned to advance these differentiated and selective SYK inhibitors by leveraging our expertise in oncology and transcriptional regulatory networks, said Norbert Bischofberger, Ph.D., President and Chief Executive Officer of Kronos.
Kronos intends to initially focus on developing the SYK inhibitor program in a biomarker-defined subset of patients with acute myelogenous leukemia (AML).
The Beat AML Trial directed by The Leukemia & Lymphoma Society has partnered closely with Gilead and looks forward to continued close collaboration with Kronos Bio.

Asana BioSciences Announces Topical Sodium Channel Blocker ASN008 Achieves Positive Results for the Treatment of Pruritus in Atopic Dermatitis; and Provides Update on JAK/SYK Inhibitor Gusacitinib in Phase 2 Studies for Chronic Hand Eczema and AD

Retrieved on:

Tuesday, March 10, 2020

Asana BioSciences announced today positive topline results from a Phase 1b study evaluating the treatment of pruritus associated with atopic dermatitis (NCT03798561) for its topical sodium channel blocker, ASN008.

Key Points:

Asana BioSciences announced today positive topline results from a Phase 1b study evaluating the treatment of pruritus associated with atopic dermatitis (NCT03798561) for its topical sodium channel blocker, ASN008.
ASN008 demonstrated low systemic exposure, and safety results show that it was well tolerated with only mild adverse events.
We are excited by these clinical data which provide proof-of-concept for ASN008 in the treatment of pruritus associated with atopic dermatitis.
Asana is also developing an oral Janus kinase (JAK) and Spleen tyrosine kinase (SYK) inhibitor, gusacitinib, for immunology/dermatology indications such as chronic hand eczema and atopic dermatitis.

Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo

Retrieved on:

Tuesday, December 3, 2019

Tyrosine kinases, Autoimmune diseases, RTT, Branches of biology, Medicine, Clinical medicine, Cerdulatinib, Syk, Vitiligo, Janus kinase, Dermatology, Dermatitis

BASEL, Switzerland and LONG BEACH, Calif., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the first patient has been dosed in its Phase 2a vitiligo clinical trial for topical cerdulatinib.

Key Points:

BASEL, Switzerland and LONG BEACH, Calif., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the first patient has been dosed in its Phase 2a vitiligo clinical trial for topical cerdulatinib.
Cerdulatinib is a dual inhibitor of the Janus kinase (JAK) and spleen tyrosine kinase (Syk) pathways, which Dermavant is evaluating as a differentiated topical treatment option for vitiligo and other inflammatory skin conditions such as atopic dermatitis.
With vitiligo affecting an estimated 65-95 million people worldwide, including approximately 2.4 million people in the U.S., I am excited to announce that the first vitiligo patient has been dosed with topical cerdulatinib in this Phase 2a clinical trial, said Todd Zavodnick, Chief Executive Officer of Dermavant.
Vitiligo is a chronic skin disease characterized by smooth, white patches of skin due to the loss of natural skin color.

WRIGHT MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Wright Medical Group N.V. - WMGI

Retrieved on:

Friday, November 8, 2019

Legal, Professional services, Foti, KSF, Syk, Stryker, Military vehicles, Vehicles, Military equipment

and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Wright Medical Group N.V. (NasdaqGS: WMGI) to Stryker Corporation (NYSE: SYK).

Key Points:

and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Wright Medical Group N.V. (NasdaqGS: WMGI) to Stryker Corporation (NYSE: SYK).
Under the terms of the proposed transaction, shareholders of Wright will receive only $30.75 in cash for each share of Wright that they own.
KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma

Retrieved on:

Friday, October 4, 2019

Clinical medicine, Medicine, Antibody-drug conjugates, Immune thrombocytopenic purpura, Syk, Organ systems, Tyrosine kinase inhibitors, Pyrimidines, Draft:Nordic Nanovector, Fostamatinib

LONDON, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase (Syk) inhibitor, in patients with relapsed or refractory lymphoma.

Key Points:

LONDON, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ( Chi-Med ) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase (Syk) inhibitor, in patients with relapsed or refractory lymphoma.
The international clinical study, with sites in the U.S. and Europe, is a multi-center, open-label, two-stage study, including dose escalation and expansion, investigating the effects of HMPL-523 administered orally to patients with relapsed or refractory lymphoma.
Preliminary results of the dose escalation stage in a Phase I study in China of HMPL-523 in patients with relapsed or refractory B-cell lymphomas were presented in 20181.
Outside of oncology, HMPL-523 is in Phase I study in patients with Immune Thrombocytopenia (ITP) in China (clinicaltrials.gov identifier: NCT03951623 ).

Asana BioSciences Strengthens Leadership Team as ASN002 Phase 2b RADIANT Trial in Atopic Dermatitis Advances with a Second Positive DSMB Recommendation

Retrieved on:

Tuesday, February 26, 2019

Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Research, FDA, Science, RTT, Type I hypersensitivity, Autoimmune diseases, Syk, Atopic dermatitis, Dermatitis, Atopy, Clinical medicine, Janus kinase inhibitor, Branches of biology

We are excited to welcome Shashank and Pablo on board, said Sandeep Gupta, PhD, Founder and CEO of Asana BioSciences.

Key Points:

We are excited to welcome Shashank and Pablo on board, said Sandeep Gupta, PhD, Founder and CEO of Asana BioSciences.
ASN002, a novel dual inhibitor of JAK and SYK kinases, is in Phase 2b development in moderate-to-severe atopic dermatitis patients (RADIANT study - NCT03654755).
We look forward to reporting the RADIANT trial outcome in atopic dermatitis in the second half of 2019, said Louis Denis, MD, Chief Medical Officer of Asana.
Asanas lead asset for immunology/dermatology indications - ASN002, a novel dual inhibitor of JAK and SYK kinases - is in Phase 2b development in moderate-to-severe atopic dermatitis patients (RADIANT study - NCT03654755).

Rigel To Present Phase 2 Results for Fostamatinib in Autoimmune Hemolytic Anemia at EHA

Retrieved on:

Tuesday, June 12, 2018

Autoimmune diseases, Medicine, Acquired hemolytic anemia, Fostamatinib, Organophosphates, Prodrugs, Clinical medicine, Autoimmune hemolytic anemia, AIHA, Warm antibody autoimmune hemolytic anemia, Syk, Protein kinase inhibitor

Title: FOSTAMATINIB, A SPLEEN TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF WARM ANTIBODY AUTOIMMUNE HEMOLYTIC ANEMIA: PRELIMINARY RESULTS OF THE SOAR PHASE 2, MULTICENTER, OPEN-LABEL STUDY

Key Points:

Title: FOSTAMATINIB, A SPLEEN TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF WARM ANTIBODY AUTOIMMUNE HEMOLYTIC ANEMIA: PRELIMINARY RESULTS OF THE SOAR PHASE 2, MULTICENTER, OPEN-LABEL STUDY
Rigel is evaluating the safety and efficacy of fostamatinib in patients with warm antibody AIHA.
On January 31, 2018, the FDA granted Orphan Drug designation to fostamatinib for the treatment of patients with AIHA.
A total of 9 of 17 (53%) evaluable patients achieved a response to fostamatinib treatment, one a late responder in the Stage 1 extension study.
Rigel's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy.

Rigel Announces FDA Approval of TAVALISSE™ (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients

Retrieved on:

Tuesday, April 17, 2018

Medicine, Blood, Tyrosine kinase inhibitors, Anatomy, Fostamatinib, Organophosphates, Prodrugs, Pyrimidines, Tyrosine kinases, Immune thrombocytopenic purpura, Syk, Thrombocytopenia

TAVALISSE is designed to inhibit SYK,a key signaling component in the body's immune process that can lead to platelet destruction in ITP patients.

Key Points:

TAVALISSE is designed to inhibit SYK,a key signaling component in the body's immune process that can lead to platelet destruction in ITP patients.
"We are excited to bring this new medicine to the population of adult patients with chronic ITP in need of additional therapies.
TAVALISSE (fostamatinib disodium hexahydrate) tablets is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
The company's first FDA approved product is TAVALISSE (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.